|
GSK PLC on Wednesday said it received two significant endorsements from a US advisory panel, bolstering its respiratory syncytial virus and meningitis vaccine portfolios. The London-based pharmaceutical company said the US Centers for Disease Control & Prevention’s advisory committee on immunization practices recommended its RSV vaccine Arexvy for adults aged 50 to 59 who are at increased risk of severe disease. This follows a prior recommendation covering adults aged 60 and above. Arexvy, already approved in over 60 countries, was supported by trial data showing safety and immune response in the 5059 age group. GSK said more than 13 million adults in the US fall into this newly covered category, including people with chronic health conditions such as asthma, diabetes, and heart disease. Chief Scientific Officer Tony Wood said: ‘RSV can have a significant impact for those with underlying medical conditions. We look forward to helping protect more people with RSV vaccination.’ The panel also endorsed GSK’s newly approved 5-in-1 meningococcal vaccine, Penmenvy, for use in people over 10 years old. The single-dose vaccine protects against serogroups A, B, C, W and Y of Neisseria meningitidis, and is designed to simplify the adolescent meningitis immunisation schedule in the US. GSK said Penmenvy, which combines components of its Bexsero and Menveo vaccines, could improve vaccination rates by reducing the number of injections required. It is expected to be available in the US starting in summer 2025. Shares in GSK were down 1.8% at 1,321.00 pence in London on Thursday morning. The wider FTSE 100 index was down 0.5%. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
